Article info
Clinical ethics
Paper
Division and discord in the Clinical Trials Regulation
- Correspondence to Dr David Shaw, Department of Health, Ethics and Society, Maastricht University, Maastricht, 6200 MD, the Netherlands; Postbus 616; d.shaw{at}maastrichtuniversity.nl
Citation
Division and discord in the Clinical Trials Regulation
Publication history
- Received January 27, 2016
- Revised May 20, 2016
- Accepted June 21, 2016
- First published July 18, 2016.
Online issue publication
October 25, 2016
Article Versions
- Previous version (18 July 2016).
- Previous version (22 July 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Other content recommended for you
- Ethical review reporting of Chinese trials records in WHO primary registries
- Diversity and inclusion for rodents: how animal ethics committees can help improve translation
- Research ethics committees: the role of ethics in a regulatory authority
- Problems and development strategies for research ethics committees in China’s higher education institutions
- Partnership as an ethical model for medical research in developing countries: the example of the “implementation trial”
- Incorporating ethical principles into clinical research protocols: a tool for protocol writers and ethics committees
- Non-equivalent stringency of ethical review in the Baltic States: a sign of a systematic problem in Europe?
- Contesting the science/ethics distinction in the review of clinical research
- Implementation of the EU clinical trial regulation transforms the ethics committee systems and endangers ethical standards
- Regulatory approval of clinical trials: is it time to reinvent the wheel?